Synthesis of Dual Target CPT-Ala-Nor Conjugates and Their Biological Activity Evaluation

Author(s): Chang K. Zhao*, Lang Xu, Xian H. Wang, Yu J. Bao, Yuhe Wang.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 19 , Issue 4 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Target therapy has been one of the important strategies in new drug discovery and the resulting drug resistance has also been a serious problem for concern. At the same time, there are several cancer genes or pathways operating within a given cancer. Given these two things, the combination therapy will be needed for optimal therapeutic effect.

Objective: Camptothecin and norcantharidin were thus chosen to construct a dual anticancer drugs assemblies mainly because CPT was the DNA-topoisomerase I inhibitor and norcantharidin could also suppress the cancer cell growth by inhibiting protein phosphatase. The designed conjugate of camptothecin and norcantharidin linked by alanine was expected to have dual target drug properties.

Methods: EDCI/DMAP was chosen as a coupling agent for the coupling of CPT with substituted norcantharidin derivatives and CCK-8 method was used to test the cytotoxicity and intensity on human hepatoma cell line HepG2. Two kinds of enzymes, Top I and CDC 25B were selected to screen the binding affinity in molecular level.

Results: Nine of dual targets camptothecin derivatives were smoothly synthesized by twice coupling in the condition of EDCI/DMAP in moderate yield. All of the synthesized compounds were characterized by 1HNMR and 13CNMR spectrum and exhibited strong potent inhibition against Hep G2, SW480, BGC803, and PANC-1 cell line in vitro. The newly synthesized camptothecin compounds, such as 3j and 3i have strengthened inhibition activity compared to camptothecin and norcantharidin.

Conclusion: We have successfully synthesized a series of novel camptothecin derivatives constructed from three components of camptothecin, alanine and norcantharidin. These compounds not only preserved strong activity against several cancer cell lines in vitro, but also exhibited potential binding affinity to target Top I and CDC 25B. Therefore, these conjugates linked by alanine could suppress cancer cell growth by inhibiting Top I and protein phosphatase simultaneously, which makes it much valuable as a novel bi-functional target drug candidate to develop in vivo.

Keywords: Camptothecin, alanine, conjugate, prodrug, norcantharidin, antitumor agents.

[1]
Wall, M.E.; Wani, M.C.; Cook, C.E. Plant antitumor agents I. The isolation and structure of camptothecin: A novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminate. J. Am. Chem. Soc., 1966, 16, 3888-3890.
[2]
Chabner, B.A.; Roberts, T.G. Timeline: Chemotherapy and the war on cancer. Nat. Rev. Cancer, 2005, 5, 65-72.
[3]
Friedl, P.; Wolf, K. Tumour-cell invasion and migration: Diversity and escape mechanisms. Nat. Rev. Cancer, 2003, 3, 362-374.
[4]
Yadav, D.K.; Khan, F. QSAR; docking and ADMET studies of camptothecin derivatives as inhibitors of DNA topoisomerase-I. J. Chemometrics, 2013, 27, 21-33.
[5]
Vishnuvajjala, B.R.; Garzon-Aburbeh, A. Water soluble prodrugs of camptothecin. U.S. Patent 4,943,579, July 24, 1990.
[6]
Jin, C.; Zhang, Q.M.; Lu, W. Synthesis and biological evaluation of hypoxia-activated prodrugs of SN-38. Eur. J. Med. Chem., 2017, 132, 135-141.
[7]
Manjeet, D.; Chao, P.Y.; Kutscher, H.L.; Gao, D.Y.; Sinko, P.J. A series of α-amino acid ester prodrugs of camptothecin: In vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity. J. Med. Chem., 2010, 53(3), 1038-1047.
[8]
Hill, T.A.; Stewart, S.G.; Sauer, B.; Gilbert, J.; Ackland, S.P.; Sakoff, J.A.; McCluskey, A. Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity. Bioorg. Med. Chem. Lett., 2007, 17, 3392-3397.
[9]
Essers, M.; Wibbeling, B.; Haufe, G. Synthesis of the first fluorinated cantharidin analogues. Tetrahedron Lett., 2001, 42, 5429-5433.
[10]
Miao, Z.Y.; Zhu, L.J.; Dong, G.Q.; Zhuang, C.L.; Wu, Y.L.; Wang, S.Z.; Guo, Z.Z.; Liu, Y.; Wu, S.C.; Zhu, S.P.; Fang, K.; Yao, J.Z.; Li, J.; Sheng, C.Q.; Zhang, W.N. A new strategy to improve the metabolic stability of lactone: Discovery of (20S; 21S)-21-Fluoro camptothecins as novel: Hydrolytically stable topoisomerase I inhibitors. J. Med. Chem., 2013, 56, 7902-7910.
[11]
Sun, P.; Chen, D.; Deng, H.P.; Wang, N.; Huang, P.; Jin, X.; Zhu, X.Y. “Bottom-up” construction of multi-polyprodrug-arm hyperbranched amphiphiles for cancer therapy. Bioconjug. Chem., 2017, 28(5), 1470-1480.
[12]
Xie, H.Y.; Xu, X.; Chen, J.M.; Li, L.L.; Wang, J.G.; Fang, T.; Zhou, L.; Wang, H.X.; Zhen, S.S. Rational design of multifunctional small-molecule prodrugs for simultaneous suppression of cancer cell growth and metastasis in vitro and in vivo. Chem. Commun., 2016, 32, 5601-5604.
[13]
Cai, Y.B.; Shen, H.S.; Zhan, J.; Lin, M.L.; Dai, L.H.; Ren, C.H.; Shi, Y.; Liu, J.F.; Gao, J.; Yang, Z.M. Supramolecular “Trojan Horse” for nuclear delivery of dual anticancer drugs. J. Am. Chem. Soc., 2017, 139(8), 2876-2879.
[14]
Wang, X.H.; Yang, F.H.; Zhao, C.K.; Gao, L.; Li, C. Sealed tube promoted coupling of camptothecin and norcantharidin acid ester and their preliminary biological activity evaluation in vitro. Med. Chem. Res., 2018, 27, 406-411.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 19
ISSUE: 4
Year: 2019
Page: [502 - 508]
Pages: 7
DOI: 10.2174/1871520619666190121121933
Price: $58

Article Metrics

PDF: 30
HTML: 5